Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overal...
Gespeichert in:
| Veröffentlicht in: | PloS one 2018-10, Vol.13 (10), p.e0197743-e0197743 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0197743 |
|---|---|
| container_issue | 10 |
| container_start_page | e0197743 |
| container_title | PloS one |
| container_volume | 13 |
| creator | Khunger, Monica Patil, Pradnya Dinkar Khunger, Arjun Li, Manshi Hu, Bo Rakshit, Sagar Basu, Arnab Pennell, Nathan Stevenson, James P Elson, Paul Panchabhai, Tanmay S Velcheti, Vamsidhar |
| description | The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab.
A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model.
Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = |
| doi_str_mv | 10.1371/journal.pone.0197743 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2125297259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A559773644</galeid><doaj_id>oai_doaj_org_article_04172441db5248ef9a0d4dcd3d834d52</doaj_id><sourcerecordid>A559773644</sourcerecordid><originalsourceid>FETCH-LOGICAL-c758t-9f23062df9c17a9cf716a832785ae8dee35ff16fa9135b5cf0a8f171904463f3</originalsourceid><addsrcrecordid>eNqNk9-L1DAQx4so3rn6H4gWBNGHrknT9MeLcBz-WDg40cPXMJtOulnaZE3Sw3v2Hzd72zu2cg9SaEv6me90vjOTJC8pWVJW0Q9bOzoD_XJnDS4JbaqqYI-SU9qwPCtzwh4fvZ8kz7zfEsJZXZZPkxNGGG9YzU6TP9-sD1lwCGFAE1K5AdOhT7VJNzhAsL3ttIQ-3YGDAQM6n-4ctlqG1KGPyT2mwaZGX9t-HGCdDtbYsEEHu5u9irEm8wP0fSox3vrRdKkEI9FFyaBjTv88eaKg9_hiei6Sq8-frs6_ZheXX1bnZxeZrHgdskbljJR5qxpJK2ikqmgJNcurmgPWLSLjStFSQUMZX3OpCNSKVrQhRVEyxRbJ64PsrrdeTPZ5kdOc502VR0MWyepAtBa2Yuf0AO5GWNDi9sC6ToALWvYoSEGrvChou-Z5UaNqgLRFK1vW1qxoeR61Pk7ZxvWArYyFOuhnovMvRm9EZ69F7BeNXYoC7yYBZ3-N6IMYtN97CAbtePvfZUN4LC2ib_5BH65uojqIBWijbMwr96LijPM4P6wsikgtH6Di1eKgZZw1peP5LOD9LCAyAX-HDkbvxerH9_9nL3_O2bdH7AahDxsfZyzoOHNzsDiA0lnvHap7kykR-1W5c0PsV0VMqxLDXh036D7objfYX3QNEQM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2125297259</pqid></control><display><type>article</type><title>Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Khunger, Monica ; Patil, Pradnya Dinkar ; Khunger, Arjun ; Li, Manshi ; Hu, Bo ; Rakshit, Sagar ; Basu, Arnab ; Pennell, Nathan ; Stevenson, James P ; Elson, Paul ; Panchabhai, Tanmay S ; Velcheti, Vamsidhar</creator><contributor>Lee, Hyun-Sung</contributor><creatorcontrib>Khunger, Monica ; Patil, Pradnya Dinkar ; Khunger, Arjun ; Li, Manshi ; Hu, Bo ; Rakshit, Sagar ; Basu, Arnab ; Pennell, Nathan ; Stevenson, James P ; Elson, Paul ; Panchabhai, Tanmay S ; Velcheti, Vamsidhar ; Lee, Hyun-Sung</creatorcontrib><description>The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab.
A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model.
Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = <5 vs NLR = ≥5 was 29.1 (16.2-40.9) vs 24.2(16.1-36.2) months respectively, p<0.001). In addition NLR increased in non-responders after two cycles of nivolumab by 6.6±21.8 as compared to responders (p = 0.027).
Post-treatment ANC, ALC and NLR are independent prognostic factors in NSCLC patients treated with nivolumab. Changes in NLR can be an early biomarker for response in NSCLC patients treated with nivolumab.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0197743</identifier><identifier>PMID: 30359383</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Biological markers ; Biology and Life Sciences ; Biomarkers ; Cancer ; Cell number ; Chemotherapy ; Dosage and administration ; Drug therapy ; Health sciences ; Hematology ; Immunotherapy ; Inflammation ; Internal medicine ; Lung cancer ; Lung diseases ; Lymphocytes ; Medical research ; Medicine and Health Sciences ; Metastasis ; Monoclonal antibodies ; Monocytes ; Neutrophils ; Nivolumab ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Oncology ; Patients ; Prognosis ; Statistical models ; Targeted cancer therapy</subject><ispartof>PloS one, 2018-10, Vol.13 (10), p.e0197743-e0197743</ispartof><rights>COPYRIGHT 2018 Public Library of Science</rights><rights>2018 Khunger et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Khunger et al 2018 Khunger et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c758t-9f23062df9c17a9cf716a832785ae8dee35ff16fa9135b5cf0a8f171904463f3</citedby><cites>FETCH-LOGICAL-c758t-9f23062df9c17a9cf716a832785ae8dee35ff16fa9135b5cf0a8f171904463f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201866/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201866/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,2915,23847,27905,27906,53772,53774,79349,79350</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30359383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Lee, Hyun-Sung</contributor><creatorcontrib>Khunger, Monica</creatorcontrib><creatorcontrib>Patil, Pradnya Dinkar</creatorcontrib><creatorcontrib>Khunger, Arjun</creatorcontrib><creatorcontrib>Li, Manshi</creatorcontrib><creatorcontrib>Hu, Bo</creatorcontrib><creatorcontrib>Rakshit, Sagar</creatorcontrib><creatorcontrib>Basu, Arnab</creatorcontrib><creatorcontrib>Pennell, Nathan</creatorcontrib><creatorcontrib>Stevenson, James P</creatorcontrib><creatorcontrib>Elson, Paul</creatorcontrib><creatorcontrib>Panchabhai, Tanmay S</creatorcontrib><creatorcontrib>Velcheti, Vamsidhar</creatorcontrib><title>Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab.
A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model.
Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = <5 vs NLR = ≥5 was 29.1 (16.2-40.9) vs 24.2(16.1-36.2) months respectively, p<0.001). In addition NLR increased in non-responders after two cycles of nivolumab by 6.6±21.8 as compared to responders (p = 0.027).
Post-treatment ANC, ALC and NLR are independent prognostic factors in NSCLC patients treated with nivolumab. Changes in NLR can be an early biomarker for response in NSCLC patients treated with nivolumab.</description><subject>Biological markers</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cell number</subject><subject>Chemotherapy</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Health sciences</subject><subject>Hematology</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Internal medicine</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lymphocytes</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Monocytes</subject><subject>Neutrophils</subject><subject>Nivolumab</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Statistical models</subject><subject>Targeted cancer therapy</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9-L1DAQx4so3rn6H4gWBNGHrknT9MeLcBz-WDg40cPXMJtOulnaZE3Sw3v2Hzd72zu2cg9SaEv6me90vjOTJC8pWVJW0Q9bOzoD_XJnDS4JbaqqYI-SU9qwPCtzwh4fvZ8kz7zfEsJZXZZPkxNGGG9YzU6TP9-sD1lwCGFAE1K5AdOhT7VJNzhAsL3ttIQ-3YGDAQM6n-4ctlqG1KGPyT2mwaZGX9t-HGCdDtbYsEEHu5u9irEm8wP0fSox3vrRdKkEI9FFyaBjTv88eaKg9_hiei6Sq8-frs6_ZheXX1bnZxeZrHgdskbljJR5qxpJK2ikqmgJNcurmgPWLSLjStFSQUMZX3OpCNSKVrQhRVEyxRbJ64PsrrdeTPZ5kdOc502VR0MWyepAtBa2Yuf0AO5GWNDi9sC6ToALWvYoSEGrvChou-Z5UaNqgLRFK1vW1qxoeR61Pk7ZxvWArYyFOuhnovMvRm9EZ69F7BeNXYoC7yYBZ3-N6IMYtN97CAbtePvfZUN4LC2ib_5BH65uojqIBWijbMwr96LijPM4P6wsikgtH6Di1eKgZZw1peP5LOD9LCAyAX-HDkbvxerH9_9nL3_O2bdH7AahDxsfZyzoOHNzsDiA0lnvHap7kykR-1W5c0PsV0VMqxLDXh036D7objfYX3QNEQM</recordid><startdate>20181025</startdate><enddate>20181025</enddate><creator>Khunger, Monica</creator><creator>Patil, Pradnya Dinkar</creator><creator>Khunger, Arjun</creator><creator>Li, Manshi</creator><creator>Hu, Bo</creator><creator>Rakshit, Sagar</creator><creator>Basu, Arnab</creator><creator>Pennell, Nathan</creator><creator>Stevenson, James P</creator><creator>Elson, Paul</creator><creator>Panchabhai, Tanmay S</creator><creator>Velcheti, Vamsidhar</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20181025</creationdate><title>Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients</title><author>Khunger, Monica ; Patil, Pradnya Dinkar ; Khunger, Arjun ; Li, Manshi ; Hu, Bo ; Rakshit, Sagar ; Basu, Arnab ; Pennell, Nathan ; Stevenson, James P ; Elson, Paul ; Panchabhai, Tanmay S ; Velcheti, Vamsidhar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c758t-9f23062df9c17a9cf716a832785ae8dee35ff16fa9135b5cf0a8f171904463f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biological markers</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cell number</topic><topic>Chemotherapy</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Health sciences</topic><topic>Hematology</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Internal medicine</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lymphocytes</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Monocytes</topic><topic>Neutrophils</topic><topic>Nivolumab</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Statistical models</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khunger, Monica</creatorcontrib><creatorcontrib>Patil, Pradnya Dinkar</creatorcontrib><creatorcontrib>Khunger, Arjun</creatorcontrib><creatorcontrib>Li, Manshi</creatorcontrib><creatorcontrib>Hu, Bo</creatorcontrib><creatorcontrib>Rakshit, Sagar</creatorcontrib><creatorcontrib>Basu, Arnab</creatorcontrib><creatorcontrib>Pennell, Nathan</creatorcontrib><creatorcontrib>Stevenson, James P</creatorcontrib><creatorcontrib>Elson, Paul</creatorcontrib><creatorcontrib>Panchabhai, Tanmay S</creatorcontrib><creatorcontrib>Velcheti, Vamsidhar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khunger, Monica</au><au>Patil, Pradnya Dinkar</au><au>Khunger, Arjun</au><au>Li, Manshi</au><au>Hu, Bo</au><au>Rakshit, Sagar</au><au>Basu, Arnab</au><au>Pennell, Nathan</au><au>Stevenson, James P</au><au>Elson, Paul</au><au>Panchabhai, Tanmay S</au><au>Velcheti, Vamsidhar</au><au>Lee, Hyun-Sung</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2018-10-25</date><risdate>2018</risdate><volume>13</volume><issue>10</issue><spage>e0197743</spage><epage>e0197743</epage><pages>e0197743-e0197743</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC, AMC and NLR, both before and after treatment with nivolumab, are indicative markers of overall survival (OS) and evaluated change in NLR as a predictive marker of response in non -small cell lung cancer (NSCLC) patients treated with nivolumab.
A total of 109 patients with advanced NSCLC treated with nivolumab were included. ANC, ALC, AMC and NLR were examined at initiation of nivolumab therapy and after two cycles. The prognostic role of ANC, ALC, AMC and NLR with OS and changes in NLR ratio were examined with Kaplan-Meier curves and proportional hazard model.
Post-treatment NLR ≥5 after two cycles of nivolumab was associated with poor OS (median OS in NLR = <5 vs NLR = ≥5 was 29.1 (16.2-40.9) vs 24.2(16.1-36.2) months respectively, p<0.001). In addition NLR increased in non-responders after two cycles of nivolumab by 6.6±21.8 as compared to responders (p = 0.027).
Post-treatment ANC, ALC and NLR are independent prognostic factors in NSCLC patients treated with nivolumab. Changes in NLR can be an early biomarker for response in NSCLC patients treated with nivolumab.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>30359383</pmid><doi>10.1371/journal.pone.0197743</doi><tpages>e0197743</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2018-10, Vol.13 (10), p.e0197743-e0197743 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2125297259 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Biological markers Biology and Life Sciences Biomarkers Cancer Cell number Chemotherapy Dosage and administration Drug therapy Health sciences Hematology Immunotherapy Inflammation Internal medicine Lung cancer Lung diseases Lymphocytes Medical research Medicine and Health Sciences Metastasis Monoclonal antibodies Monocytes Neutrophils Nivolumab Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Prognosis Statistical models Targeted cancer therapy |
| title | Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T16%3A06%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post-treatment%20changes%20in%20hematological%20parameters%20predict%20response%20to%20nivolumab%20monotherapy%20in%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=PloS%20one&rft.au=Khunger,%20Monica&rft.date=2018-10-25&rft.volume=13&rft.issue=10&rft.spage=e0197743&rft.epage=e0197743&rft.pages=e0197743-e0197743&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0197743&rft_dat=%3Cgale_plos_%3EA559773644%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2125297259&rft_id=info:pmid/30359383&rft_galeid=A559773644&rft_doaj_id=oai_doaj_org_article_04172441db5248ef9a0d4dcd3d834d52&rfr_iscdi=true |